Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tenax TherapeuticsTENX -7.32%22 Peter Lynch Fair Value is $-35.00 as of Jul. 22, 2026. GuruFocus rates TENX with a GF Score™ of 22/100. The stock has 2 warning signs investors should review. Among 66 Biotechnology companies, Tenax Therapeutics ranks worse than 1515150% on this metric.
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
Here, as of today, Tenax Therapeutics's PEG is 1. Tenax Therapeutics's 5-Year TTM EBITDA Growth Rate is 25.
Tenax Therapeutics's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was $-1.40. Therefore, the Peter Lynch Fair Value for today is $-35.00.
As of today (2026-07-22), Tenax Therapeutics's share price is $14.560686. Tenax Therapeutics's Peter Lynch fair value is $-35.00. Therefore, Tenax Therapeutics's Price to Peter Lynch Fair Value Ratio for today is N/A.
The historical rank and industry rank for Tenax Therapeutics's Peter Lynch Fair Value or its related term are showing as below:
TENX's Price-to-Peter-Lynch-Fair-Value is not ranked *
in the Biotechnology industry.
Industry Median: 1.21 * Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.
Tenax Therapeutics (NAS:TENX) Peter Lynch Fair Value Explanation
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.
Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.
Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 25 instead of 15 in this case.
Tenax Therapeutics's Price to Peter Lynch Fair Value Ratio for today is calculated as
Price to Peter Lynch Fair Value
=
Share Price
/
Peter Lynch Fair Value
=
14.560686
/
-35.00
=
N/A
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tenax Therapeutics Peter Lynch Fair Value Related Terms
Tenax Therapeutics Peter Lynch Fair Value Historical Data
* Premium members only.
The historical data trend for Tenax Therapeutics's Peter Lynch Fair Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TENX vs RCKT, AVIR, VNDA: Peter Lynch Fair Value Comparison
For the Biotechnology subindustry, Tenax Therapeutics's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tenax Therapeutics Price-to-Peter-Lynch-Fair-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tenax Therapeutics's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:
* The bar in red indicates where Tenax Therapeutics's Price-to-Peter-Lynch-Fair-Value falls into.
Tenax Therapeutics's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.40.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.
If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.
If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.
What does a Peter Lynch Fair Value of $-35.00 mean?
Tenax Therapeutics (TENX) has a Peter Lynch Fair Value of $-35.00 as of Jul. 22, 2026. Peter Lynch Fair Value is the stock value based on a company's current earnings and five-year earnings growth, assuming a PEG of one. View historical data on Tenax Therapeutics and its competitors. According to the industry distribution chart, Tenax Therapeutics ranks #999999 out of 66 companies in the Biotechnology industry.
Is Tenax Therapeutics' Peter Lynch Fair Value too high?
Tenax Therapeutics' current Peter Lynch Fair Value is $-35.00. Based on the distribution chart, Tenax Therapeutics ranks #999999 out of 66 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Tenax Therapeutics has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Tenax Therapeutics' Peter Lynch Fair Value compare to RCKT and AVIR?
According to the Biotechnology industry distribution chart, Tenax Therapeutics ranks #999999 out of 66 companies for Peter Lynch Fair Value. This places Tenax Therapeutics in the lower half of its industry. The industry median Peter Lynch Fair Value is 1.21. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Peter Lynch Fair Value for a Biotechnology company?
The median Peter Lynch Fair Value among Biotechnology companies is 1.21, based on 66 companies in the industry. Companies in the top quartile (top 25%) have a Peter Lynch Fair Value significantly above this median, while those in the bottom quartile fall well below. However, Peter Lynch Fair Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Peter Lynch Fair Value mean?
A high Peter Lynch Fair Value can signal that a stock is expensive relative to its fundamentals. Peter Lynch Fair Value is the stock value based on a company's current earnings and five-year earnings growth, assuming a PEG of one. View historical data on Tenax Therapeutics and its competitors. For the Biotechnology industry, the median Peter Lynch Fair Value is 1.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tenax Therapeutics's current Peter Lynch Fair Value is $-35.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tenax Therapeutics stock overvalued right now?
Tenax Therapeutics (TENX) has a current Peter Lynch Fair Value of $-35.00. The current Peter Lynch Fair Value is $-35.00. Tenax Therapeutics' overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Peter Lynch Fair Value calculated?
Peter Lynch Fair Value is calculated from a company's financial statements. For Tenax Therapeutics (TENX), the current Peter Lynch Fair Value is $-35.00 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.
22GF Score
Get the complete analysis for TENX
Peter Lynch Fair Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TENX has been successfully added to your 
